Posted by Michael Wonder on 21 Jan 2023
Stop blaming Biogen for putting profit at the expense of patients. Blame the systems that enabled it.
17 January 2023 - Two congressional committees recently released damning results of an 18 month investigation into the FDA’s approval of Biogen’s controversial Alzheimer’s drug, Aduhelm.
The systems that enabled Biogen’s actions, however, went largely unscrutinised.
